They enrolled 280 patients in a trial that compared the standard eflornithine regimen with one in which only 14 infusions of that drug were given over a week's time, combined with 10 days of nifurtimox, an
oral drug licensed against Chagas
disease — which is also caused by Trypanosoma parasites — but not considered
active enough as a standalone HAT drug.